S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
Buy THIS stock before Taiwan is attacked (Ad)
UK travelers face hours-long waits for ferries to France
Intensity and insults rise as lawmakers debate debt ceiling
Bank Accounts: Frozen! (Ad)
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
Buy THIS stock before Taiwan is attacked (Ad)
'War of the states': EV, chip makers lavished with subsidies
Lanterns and crescents: more retailers court Ramadan buyers
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
Buy THIS stock before Taiwan is attacked (Ad)
UK travelers face hours-long waits for ferries to France
Intensity and insults rise as lawmakers debate debt ceiling
Bank Accounts: Frozen! (Ad)
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
Buy THIS stock before Taiwan is attacked (Ad)
'War of the states': EV, chip makers lavished with subsidies
Lanterns and crescents: more retailers court Ramadan buyers
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
Buy THIS stock before Taiwan is attacked (Ad)
UK travelers face hours-long waits for ferries to France
Intensity and insults rise as lawmakers debate debt ceiling
Bank Accounts: Frozen! (Ad)
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
Buy THIS stock before Taiwan is attacked (Ad)
'War of the states': EV, chip makers lavished with subsidies
Lanterns and crescents: more retailers court Ramadan buyers
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
Buy THIS stock before Taiwan is attacked (Ad)
UK travelers face hours-long waits for ferries to France
Intensity and insults rise as lawmakers debate debt ceiling
Bank Accounts: Frozen! (Ad)
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
Buy THIS stock before Taiwan is attacked (Ad)
'War of the states': EV, chip makers lavished with subsidies
Lanterns and crescents: more retailers court Ramadan buyers
NASDAQ:CING

Cingulate - CING Stock Forecast, Price & News

$0.98
-0.04 (-3.90%)
(As of 03/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$0.98
▼
$1.06
50-Day Range
$0.91
▼
$1.85
52-Week Range
$0.66
▼
$2.04
Volume
53,730 shs
Average Volume
435,590 shs
Market Capitalization
$11.14 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

CING stock logo

About Cingulate (NASDAQ:CING) Stock

Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

Receive CING Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cingulate and its competitors with MarketBeat's FREE daily newsletter.

CING Stock News Headlines

March 15, 2023 | msn.com
Cingulate stock slumps ~15% on commercialization pact for ADHD drug CTx-1301
March 13, 2023 | msn.com
Cingulate Tanks on Teaming Up with Indegene for ADHD Drug
April 1, 2023 | Vantage Point (Ad)
What To Do With Your Trades Today
There’s a tool that scans and picks the best stocks… and could give you all the consistency you need in your trading… No matter what happens in the market. Revealed Here: A.I. Predicted Stock Forecasts pixel
March 13, 2023 | bizjournals.com
Cingulate signs agreement to market its first drug candidate
March 13, 2023 | finance.yahoo.com
Cingulate and Indegene Announce Joint Commercialization Agreement for Lead ADHD Candidate CTx-1301
March 10, 2023 | finance.yahoo.com
Cingulate Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical and Business Update
March 10, 2023 | marketwatch.com
Cingulate Shares Slide 19% on Stock Offering
March 10, 2023 | finance.yahoo.com
Cingulate Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical and Business Update
April 1, 2023 | Vantage Point (Ad)
What To Do With Your Trades Today
There’s a tool that scans and picks the best stocks… and could give you all the consistency you need in your trading… No matter what happens in the market. Revealed Here: A.I. Predicted Stock Forecasts pixel
March 9, 2023 | msn.com
Information overload: Is all this technology bad for your brain?
March 9, 2023 | benzinga.com
EVP and COO at Cingulate Acquires Company Stock Options Worth 40,000 Shares
March 9, 2023 | benzinga.com
Cingulate Chief Executive Officer Awarded $126K Worth of Stock Options
March 5, 2023 | msn.com
New remains of multiple extinct species excavated on Chilean coast
March 4, 2023 | finance.yahoo.com
Why Cingulate Shares Are Trading Higher Today
March 3, 2023 | msn.com
What Is the Default Mode Network?
February 24, 2023 | msn.com
Cingulate Pops after Positive Topline Data
February 24, 2023 | benzinga.com
Thinking about buying stock in Beyond Meat, ACM Research, Farfetch, Protalix Biotherapeutics, or Cingulate?
February 24, 2023 | finance.yahoo.com
Cingulate stock skyrockets after ADHD treatment shows positive trial results
February 24, 2023 | investorplace.com
Why Is Cingulate (CING) Stock Up 72% Today?
February 24, 2023 | msn.com
HUMBL stock dips 2%, cancels reverse stock split
February 23, 2023 | msn.com
Cingulate pops ~76% after hours on trial results for its ADHD treatment drug
February 23, 2023 | finance.yahoo.com
Cingulate Announces Positive Top-Line Results from Fed/Fast Study of Lead Asset CTx-1301 for ADHD
February 16, 2023 | msn.com
Racism takes a toll on the brain, research shows
February 15, 2023 | marketwatch.com
Postpartum Depression Management Market Share, Size, Share, Industry Trends, Demand, Overview and Forecast 2022 to 2028
February 11, 2023 | msn.com
Researchers identify a potential neural signature of social belonging
February 10, 2023 | msn.com
Obese individuals have reduced grey matter density and functional brain abnormalities, study finds
February 3, 2023 | msn.com
Can Ketamine alleviate depression from chronic pain?
See More Headlines
Receive CING Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cingulate and its competitors with MarketBeat's FREE daily newsletter.

CING Company Calendar

Today
4/01/2023
Next Earnings (Estimated)
5/11/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CING
CUSIP
N/A
CIK
1862150
Web
www.cingulate.com
Phone
913-942-2300
Fax
N/A
Employees
16
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($1.57)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-17,680,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-174.78%
Return on Assets
-119.80%

Debt

Debt-to-Equity Ratio
0.01
Current Ratio
1.12
Quick Ratio
1.12

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.34 per share
Price / Book
2.90

Miscellaneous

Outstanding Shares
11,310,000
Free Float
7,772,000
Market Cap
$11.14 million
Optionable
Not Optionable
Beta
0.06

Key Executives

  • Dr. Shane J. Schaffer Pharm.D. (Age 48)
    PharmD, CEO & Chairman
    Comp: $475k
  • Mr. Louis G. Van Horn CPA (Age 64)
    M.B.A., Exec. VP & CFO
    Comp: $380k
  • Dr. Laurie A. Myers M.B.A. (Age 66)
    Ph.D., Exec. VP & COO
    Comp: $400k
  • Mr. Craig S. Gilgallon Esq. (Age 50)
    Exec. VP, Gen. Counsel & Board Sec.
    Comp: $380k
  • Dr. Raul R. Silva M.D. (Age 65)
    Exec. VP & Chief Science Officer
  • Thomas Dalton
    Head of Investor & PR
  • Dr. Matthew N. Brams M.D. (Age 59)
    Exec. VP & Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













CING Stock - Frequently Asked Questions

Should I buy or sell Cingulate stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cingulate in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CING shares.
View CING analyst ratings or view top-rated stocks.

How have CING shares performed in 2023?

Cingulate's stock was trading at $1.00 at the beginning of the year. Since then, CING shares have decreased by 1.5% and is now trading at $0.9850.
View the best growth stocks for 2023 here.

Are investors shorting Cingulate?

Cingulate saw a decline in short interest in the month of March. As of March 15th, there was short interest totaling 404,000 shares, a decline of 62.2% from the February 28th total of 1,070,000 shares. Based on an average daily volume of 848,400 shares, the days-to-cover ratio is presently 0.5 days. Currently, 5.3% of the shares of the company are sold short.
View Cingulate's Short Interest.

When is Cingulate's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 11th 2023.
View our CING earnings forecast.

When did Cingulate IPO?

(CING) raised $29 million in an IPO on Wednesday, December 8th 2021. The company issued 4,166,666 shares at a price of $6.00-$8.00 per share.

What is Cingulate's stock symbol?

Cingulate trades on the NASDAQ under the ticker symbol "CING."

How do I buy shares of Cingulate?

Shares of CING stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cingulate's stock price today?

One share of CING stock can currently be purchased for approximately $0.99.

How much money does Cingulate make?

Cingulate (NASDAQ:CING) has a market capitalization of $11.14 million. The company earns $-17,680,000.00 in net income (profit) each year or ($1.57) on an earnings per share basis.

How can I contact Cingulate?

The official website for the company is www.cingulate.com. The company can be reached via phone at 913-942-2300 or via email at ir@cingulate.com.

This page (NASDAQ:CING) was last updated on 4/1/2023 by MarketBeat.com Staff